Security Snapshot

BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 Institutional Ownership

CUSIP: 10806XAD4

13F Institutional Holders and Ownership History from Q1 2022 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

22

Principal

$157.91MFull value: $157,913,000 · USD principal · 30 Sep 2026

Price (% of par)

102.51%

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 3 signals
Principal change
-$14,183,000
Market value change
-$14,628,238
Number of holders
22
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported market price (% of par)
102.51%
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • 10806XAD4 - BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0 is tracked under CUSIP 10806XAD4.
  • 22 institutions reported positions in Q3 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 39 to 22 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $782.48MFull value: $782,478,316 · USD · 30 Jun 2026
    to
    $162.48MFull value: $162,483,448 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 22 institutions filings for Q3 2026.

Open SEC evidence

Security key

10806XAD4

13F reference period

Q3 2026

13F holders

22

13D/G owners

0

CIK / CUSIP context first

As of 30 Sep 2026, 22 institutional investors reported holding
$157.91MFull value: $157,913,000 · USD · 30 Sep 2026 · Principal (par value)
in principal (par value) of BRIDGEBIO PHARMA INC - NOTE 2.250% 2/0.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
19
Headline period
Q3 2026
Rows shown
1-19 of 19
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q3 $157,913,000 $162,483,448 -$14,628,238 102.51% 22
2026 Q2 $704,526,000 $782,478,316 -$25,521,870 110.87% 39
2026 Q1 $725,230,100 $814,740,721 -$5,434,737 112.22% 42
2025 Q4 $725,396,220 $818,374,562 +$127,111,148 112.61% 41
2025 Q3 $627,523,074 $621,164,871 -$32,020,133 98.82% 42
2025 Q2 $677,587,704 $702,102,373 -$9,786,616 93.58% 40
2025 Q1 $692,365,423 $625,022,166 +$61,676,686 90.0% 41
2024 Q4 $627,730,524 $538,661,074 -$2,449,849 85.63% 38
2024 Q3 $632,466,339 $531,505,798 -$6,333,280 83.61% 38
2024 Q2 $641,592,339 $515,193,030 -$52,483,886 80.12% 42
2024 Q1 $705,552,289 $610,874,985 -$20,650,206,952 81.93% 44
2023 Q4 $738,008,709 $628,227,229 +$26,540,307 84.69% 41
2023 Q3 $709,803,792 $535,567,910 +$79,827,117 75.0% 45
2023 Q2 $610,911,952 $378,751,579 -$2,520,238 61.77% 41
2023 Q1 $623,666,127 $401,644,918 +$18,976,107 63.93% 44
2022 Q4 $622,846,458 $239,898,646 -$41,611,016 38.23% 35
2022 Q3 $580,552,458 $262,269,316 +$1,575,782 44.15% 33
2022 Q2 $594,504,458 $253,628,177 -$25,432,130 40.87% 34
2022 Q1 $625,412,958 $310,645,005 +$309,619,000 47.62% 36
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .